Focused Wealth Management’s Voyager Therapeutics VYGR Stock Holding History

Focused Wealth Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$76K	–	1094
2022 Q1	$76K	Hold	10,000	–	–	0.01%	257
2021 Q4	$27K	Buy	+10,000	New	+$34.1K	﹤0.01%	454
2021 Q3	–	Sell	-25,000	Closed	-$103K	–	1114
2021 Q2	$103K	Buy	+25,000	New	+$113K	0.02%	286
2019 Q4	–	Sell	-1,000	Closed	-$17K	–	778
2019 Q3	$17K	Hold	1,000	–	–	﹤0.01%	411
2019 Q2	$27K	Hold	1,000	–	–	0.01%	382
2019 Q1	$19K	Hold	1,000	–	–	0.01%	385
2018 Q4	$9K	Hold	1,000	–	–	﹤0.01%	476
2018 Q3	$19K	Hold	1,000	–	–	0.01%	374
2018 Q2	$20K	Sell	1,000 -1,000	-50%	-$19.8K	0.01%	362
2018 Q1	$38K	Sell	2,000 -2,000	-50%	-$43.2K	0.01%	322
2017 Q4	$66K	Buy	4,000 +2,000	+100%	+$34.3K	0.02%	274
2017 Q3	$41K	Buy	+2,000	New	+$22.6K	0.01%	262

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Focused Wealth Management's VYGR Position: Q2 2022 in Review

Focused Wealth Management sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 10,000 shares — an estimated $76K sold.

Focused Wealth Management first reported a position in VYGR in Q3 2017 and held it in 12 quarters. The position peaked at $103K in Q2 2021. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

Focused Wealth Management reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
Focused Wealth Management sold 10,000 Voyager Therapeutics shares in Q2 2022, an estimated $76K.
Focused Wealth Management first reported a position in Voyager Therapeutics in Q3 2017 and held it in 12 quarters.
Focused Wealth Management's Voyager Therapeutics position peaked at $103K in Q2 2021.
78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on Focused Wealth Management's 13F filing for Q2 2022, filed 4 Aug 2022.